Randomized phase II study of nintedanib in metastatic castration-resistant prostate cancer postdocetaxel

Anti-cancer drugs

Volumn 25, Issue 9, 2014, Pages 1081-1088

  Droz, Jean Pierre ^a   Medioni, Jaques ^a   Chevreau, Christine ^a   De Mont Serrat, Helene ^a   Merger, Michael ^a   Stopfer, Peter ^a   Kaiser, Rolf ^a   Oudard, Stephane ^a  

^a UNIVERSITÉ LYON 1   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; DOCETAXEL; INDOLE DERIVATIVE; NINTEDANIB; TAXOID; TUBULIN MODULATOR;

ADENOCARCINOMA; AGED; CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; DISEASE FREE SURVIVAL; HUMAN; MALE; MIDDLE AGED; MULTICENTER STUDY; PATHOLOGY; PHASE 2 CLINICAL TRIAL; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; RANDOMIZED CONTROLLED TRIAL; SECONDARY; VERY ELDERLY;

ADENOCARCINOMA; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; HUMANS; INDOLES; MALE; MIDDLE AGED; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; TAXOIDS; TUBULIN MODULATORS;

EID: 85027944730     PISSN: None     EISSN: 14735741     Source Type: Journal    
DOI: 10.1097/CAD.0000000000000131     Document Type: Article

References (0)